Comparison between Invicta Diagnostic IPO and Telge Projects IPO.
Invicta Diagnostic IPO is a SME Bookbuilding IPO proposed to list at NSE SME while Telge Projects IPO is a SME Bookbuilding proposed to list at BSE SME.
| Invicta Diagnostic IPO | Telge Projects IPO | |
|---|---|---|
| Logo |  |  |
| Issue Category | SME | SME |
| Issue Type | IPO | IPO |
| Process Type | Bookbuilding | Bookbuilding |
| Listing At | NSE SME | BSE SME |
| Lead Managers | Socradamus Capital Pvt.Ltd. | Smart Horizon Capital Advisors Pvt.Ltd. |
| Registrar | Bigshare Services Pvt.Ltd. | Bigshare Services Pvt.Ltd. |
| Market Maker | Nikunj Stock Brokers Ltd. | Shreni Shares Ltd. |
| DRHP | DRHP  | DRHP |
| RHP | RHP | RHP |
| Final Prospectus | Final Prospectus | Final Prospectus |
| Anchor Investor | Anchor Investor | Anchor Investor |
| IPO Allotment URL | IPO Allotment URL | IPO Allotment URL |
The total issue size of Invicta Diagnostic IPO is up to ₹26.71 Cr whereas the issue size of the Telge Projects IPO is up to ₹25.87 Cr. The final issue price of Invicta Diagnostic IPO is ₹85.00 per share and of Telge Projects IPO is ₹105.00 per share.
| Invicta Diagnostic IPO | Telge Projects IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹80.00 per share | ₹95.00 per share |
| Issue Price (Upper) | ₹85.00 per share | ₹105.00 per share |
| Issue Price (Final) | ₹85.00 per share | ₹105.00 per share |
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | 1600 shares | 1200 shares |
| Fresh Issue Size | 31,42,400 shares | 24,63,600 shares |
| Fresh Issue Size (Amount) | up to ₹26.71 Cr | up to ₹25.87 Cr |
| OFS Issue Size | 0 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| Issue Size Total | 31,42,400 shares | 24,63,600 shares |
| Issue Size Total (Amount) | up to ₹26.71 Cr | up to ₹25.87 Cr |
Invicta Diagnostic IPO opens on Dec 01, 2025, while Telge Projects IPO opens on Sep 25, 2025. The closing date of Invicta Diagnostic IPO and Telge Projects IPO is Dec 03, 2025, and Sep 29, 2025, respectively.
| Invicta Diagnostic IPO | Telge Projects IPO | |
|---|---|---|
| Anchor Bid Date | Nov 28, 2025 | Sep 24, 2025 |
| Issue Open | Dec 01, 2025 | Sep 25, 2025 |
| Issue Close | Dec 03, 2025 | Sep 29, 2025 |
| Basis Of Allotment (Tentative) | Dec 04, 2025 | Sep 30, 2025 |
| Initiation of Refunds (Tentative) | Dec 05, 2025 | Oct 01, 2025 |
| Credit of Share (Tentative) | Dec 05, 2025 | Oct 01, 2025 |
| Listing date (Tentative) | Dec 08, 2025 | Oct 03, 2025 |
| Anchor Lockin End date 1 | Jan 02, 2026 | Oct 29, 2025 |
| Anchor Lockin End date 2 | Mar 03, 2026 | Dec 28, 2025 |
Invicta Diagnostic IPO P/E ratio is 14.51, as compared to Telge Projects IPO P/E ratio of 14.04.
| Invicta Diagnostic IPO | Telge Projects IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated Consolidated)Invicta Diagnostic Ltd.'s revenue increased by 90% and profit after tax (PAT) rose by 30% between the financial year ending with March 31, 2025 and March 31, 2024.
| Company Financials (Restated Consolidated)Telge Projects Ltd.'s revenue increased by 105% and profit after tax (PAT) rose by 103% between the financial year ending with March 31, 2025 and March 31, 2024.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 90.52 | 97.28 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 66.69 | 71.50 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 14.51 | 14.04 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹106.86 Cr. | ₹102.80 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 44.28% | 67.29% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 42.00% | 56.22% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 0.26 | 0.83 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹5.86 | ₹7.48 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 36.25% | 47.46% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Invicta Diagnostic IPO Retail Individual Investors (RII) are offered 12,67,200 shares while in Telge Projects IPO retail investors are offered 12,67,200 shares. Qualified Institutional Buyers (QIB) are offered 5,34,400 shares in Invicta Diagnostic IPO and 4,92,000 shares in Telge Projects IPO.
| Invicta Diagnostic IPO | Telge Projects IPO | |
|---|---|---|
| Anchor Investor Reservation | 7,98,400 shares | 7,33,200 shares |
| Market Maker Reservation | 1,66,400 shares | 1,30,800 shares |
| QIB | 5,34,400 shares | 4,92,000 shares |
| NII | 5,42,400 shares | 3,72,000 shares |
| RII | 12,67,200 shares | 8,66,400 shares |
| Employee | 0 shares | 0 shares |
| Others | ||
| Total | 31,42,400 shares | 24,63,600 shares |
Invicta Diagnostic IPO subscribed 4.27x in total, whereas Telge Projects IPO subscribed 2.99x.
| Invicta Diagnostic IPO | Telge Projects IPO | |
|---|---|---|
| QIB (times) | 3.51x | 5.41x |
| NII (times) | 6.96x | 2.75x |
| Big NII (times) | 7.30x | 3.00x |
| Small NII (times) | 6.27x | 2.26x |
| RII (times) | 3.44x | 1.72x |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 4.27x | 2.99x |
